Bioinformatics role in Drug discovery

Authors

  • Sharmishta Hangloo Ph.d Scholar, Department of Biotechnology, Sher-e-Kashmir University of Agricultural Science and Technology, Jammu, Jammu & Kashmir, India.
  • Gazi Muhammad Abdullah Mahdi Ph.d Scholar, Department of Biotechnology, Sher-e-Kashmir University of Agricultural Science and Technology, Jammu, Jammu & Kashmir, India.

Keywords:

Bioinformatics, Drug discovery, distinguishing proof, lead optimization, medicate

Abstract

Drug discovery is a strenuous, time devouring and costly prepare requiring a few a long time and a colossal sum of financing. Distinguishing a potential medicate target and appropriate lead atom for medicate improvement are basic steps within the medicate disclosure handle. Among the different strategies accessible for the recognizable proof of unused lead molecules, basic bioinformatics features an uncommon put. Basic bioinformatics plays an imperative part in target approval, dynamic location distinguishing proof, lead optimization, drug-likeness expectation and steadiness investigation. The basic bioinformatics makes a difference in distinguishing and planning novel leads against a chosen medicate target that can be tried tentatively to check the affect on the natural framework.

References

Chukwudozie OS, Duru VC, Ndiribe CC, et al. The relevance of bioinformatics applications in the discovery of vaccine candidates and potential drugs for COVID-19 treatment. Bioinformatics and Biology Insights. 2021;15:11779322211002168.

Ullah MA, Sarkar B, Islam SS. Exploiting the reverse vaccinology approach to design novel subunit vaccines against Ebola virus. Immunobiology. 2020;225(3):151949.

Seib KL, Zhao X, Rappuoli R. Developing vaccines in the era of genomics: a decade of reverse vaccinology. Clinical Microbiology and Infection. 2012;18:109–16.

Rappuoli R. Reverse vaccinology. Current opinion in microbiology. 2000;3(5):445–50.

Adu-Bobie J, Capecchi B, Serruto D, et al. Two years into reverse vaccinology. Vaccine. 2003;21(7-8):605–10.

Doytchinova, IA, DR. VaxiJen: a server for prediction of protective antigens, tumor antigens and subunit vaccines. BMC Bioinformatics. 2007;8:4.

María RR, Arturo CJ, Alicia JA, et al. The impact of bioinformatics on vaccine design and development. Vaccines. 2017;2:3–6.

Chaudhary M, Kumar N, Baldi A, et al J. 4-Bromo-4’-chloro pyrazoline analog of curcumin augmented anticancer activity against human cervical cancer, HeLa cells: in silico-guided analysis, synthesis, and in vitro cytotoxicity. Journal of Biomolecular Structure and Dynamics. 2020;38(5):1335–53.

Ong E, Wong MU, Huffman A, He Y. COVID-19 coronavirus vaccine design using reverse vaccinology and machine learning. Front Immunol 11: 1581.

Iskar M, Zeller G, Zhao XM, et al. Drug discovery in the age of systems biology: the rise of computational approaches for data integration. Current opinion in biotechnology. 2012;23(4):609–16.

Katara P. Role of bioinformatics and pharmacogenomics in drug discovery and development process. Network Modeling Analysis in Health Informatics and Bioinformatics. 2013;2(4):225–30.

Song CM, Lim SJ, Tong JC. Recent advances in computer-aided drug design. Briefings in bioinformatics. 2009;10(5):579–91.

Katara P. Role of bioinformatics and pharmacogenomics in drug discovery and development process. Network Modeling Analysis in Health Informatics and Bioinformatics. 2013;2(4):225–30.

Ratti E, Trist D. Continuing evolution of the drug discovery process in the pharmaceutical industry. Pure and applied chemistry. 2001;73(1):67–75.

Whittaker PA. What is the relevance of bioinformatics to pharmacology?. Trends in Pharmacological Sciences. 2003;24(8):434–9.

Yamanishi Y, Kotera M, Kanehisa M, Goto S. Drug-target interaction prediction from chemical, genomic and pharmacological data in an integrated framework. Bioinformatics. 2010;26(12):i246–54.

Liang BA, Mackey T. Direct-to-consumer advertising with interactive internet media: global regulation and public health issues. Jama. 2011 ;305(8):824-5.

Meyers S, Baker A (2001) Drug discovery: an operating model for a new era. Nat Biotechnol 19:727–730.

Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet journal of rare diseases. 2011;6(1):1–8.

Katara P. Role of bioinformatics and pharmacogenomics in drug discovery and development process. Network Modeling Analysis in Health Informatics and Bioinformatics. 2013;2(4):225–30.

Adams CP, Brantner VV. Spending on new drug development 1. Health economics. 2010;19(2):130–41.

Katara P. Role of bioinformatics and pharmacogenomics in drug discovery and development process. Network Modeling Analysis in Health Informatics and Bioinformatics. 2013;2(4):225–30.

Liou SY, Stringer F, Hirayama M. The impact of pharmacogenomics research on drug development. Drug metabolism and pharmacokinetics. 2012;27(1):2–8.

Rioux PP. Clinical trials in pharmacogenetics and pharmacogenomics: methods and applications. American journal of health-system pharmacy. 2000;57(9):887–98.

Nelson MR, Bacanu SA, Mosteller M, et al Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions. The pharmacogenomics journal. 2009;9(1):23–33.

Downloads

Published

2022-09-02

Issue

Vol. 9 No. 2 (2022)

Section

Review Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.